STOCK TITAN

Kiniksa COO Ross Moat sells 103,585 shares

Ross Moat's reported sales were made under a 10b5-1 plan executed July 29, 2026.

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc (KNSA) Chief Operating Officer Ross Moat exercised options for 97,572 Class A ordinary shares on October 30 and November 2, 2026, at the reported exercise prices. He sold 103,585 shares on those dates under a 10b5-1 plan executed July 29, 2026. Reported weighted-average prices included $92.00 per share for 37,775 shares and $93.15 per share for 11,642 shares; sales were executed in multiple trades through a broker-dealer.

Insider Moat Ross
Role CHIEF OPERATING OFFICER
Sold 103,585 shs ($9.63M)
Approx. gross sale proceeds $9.63M
Approx. exercise cost $1.54M
Type Security Shares Price Value
Exercise Share Option F1, F16 9,412 $0.00 $0.00
Exercise Share Option F1, F17 12,302 $0.00 $0.00
Exercise Share Option F1, F14 6,263 $0.00 $0.00
Exercise Class A Ordinary Share F1 9,412 $18.06 $170K
Exercise Class A Ordinary Share F1 12,302 $21.77 $268K
Exercise Class A Ordinary Share F1 6,263 $22.89 $143K
Sale Class A Ordinary Share F1, F9 6,681 $91.23 $610K
Sale Class A Ordinary Share F1, F10 8,932 $92.05 $822K
Sale Class A Ordinary Share F1, F11 11,642 $93.15 $1.08M
Sale Class A Ordinary Share F1, F12 722 $94.05 $68K
Exercise Share Option F1, F13 16,111 $0.00 $0.00
Exercise Share Option F1, F14 21,059 $0.00 $0.00
Exercise Share Option F1, F14 3,760 $0.00 $0.00
Exercise Share Option F1, F14 1,658 $0.00 $0.00
Exercise Share Option F1, F15 16,112 $0.00 $0.00
Exercise Share Option F1, F16 10,895 $0.00 $0.00
Exercise Class A Ordinary Share F1 16,111 $10.76 $173K
Exercise Class A Ordinary Share F1 21,059 $11.10 $234K
Exercise Class A Ordinary Share F1 3,760 $11.97 $45K
Exercise Class A Ordinary Share F1 1,658 $12.97 $22K
Exercise Class A Ordinary Share F1 16,112 $17.76 $286K
Exercise Class A Ordinary Share F1 10,895 $18.06 $197K
Sale Class A Ordinary Share F1, F2 37,775 $92.00 $3.48M
Sale Class A Ordinary Share F1, F3 15,114 $92.81 $1.40M
Sale Class A Ordinary Share F1, F4 8,430 $93.97 $792K
Sale Class A Ordinary Share F1, F5 6,282 $94.92 $596K
Sale Class A Ordinary Share F1, F6 3,672 $96.03 $353K
Sale Class A Ordinary Share F1, F7 1,760 $97.10 $171K
Sale Class A Ordinary Share F1, F8 2,575 $97.76 $252K
Holdings After Transaction: Share Option — 86,565 contracts (Direct); Class A Ordinary Share — 10,294 shares (Direct)
Footnotes (17)
  1. F1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 29, 2026.
  2. F2. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $91.36 to $92.35. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  3. F3. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $92.36 to $93.31. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  4. F4. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $93.37 to $94.36. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  5. F5. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $94.375 to $95.215. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  6. F6. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $95.485 to $96.405. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  7. F7. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $96.54 to $97.48. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  8. F8. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $97.60 to $98.30. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  9. F9. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $90.64 to $91.63. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  10. F10. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $91.64 to $92.525. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  11. F11. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $92.732 to $93.725. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  12. F12. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $93.94 to $94.135. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  13. F13. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2023.
  14. F14. The option is fully vested and exercisable.
  15. F15. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.
  16. F16. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2024.
  17. F17. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2025.
Shares acquired through option exercises 97,572 shares October 30 and November 2, 2026
Shares sold 103,585 shares October 30 and November 2, 2026
Option exercise prices $10.76, $11.10, $11.97, $12.97, $17.76, $18.06, $21.77 and $22.89 per share Options exercised on October 30 and November 2, 2026
Shares sold at weighted-average price 37,775 shares at $92.00 per share October 30, 2026
Shares sold at weighted-average price 15,114 shares at $92.81 per share October 30, 2026
Shares sold at weighted-average price 11,642 shares at $93.15 per share November 2, 2026
10b5-1 plan regulatory
"transaction was effected pursuant to a 10b5-1 plan"
A 10b5-1 plan is a pre-arranged strategy that allows company insiders to buy or sell their shares at predetermined times and prices, even while they are aware of confidential information. It acts like a scheduled appointment for trading, helping ensure transactions happen transparently and legally, which can reassure investors that trades are not based on insider knowledge.
weighted average sales price financial
"reflects a weighted average sales price"
vesting commencement date technical
"The vesting commencement date is April 1, 2023"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KNSA shares did Ross Moat sell?

Ross Moat reported sales of 103,585 Class A ordinary shares on October 30 and November 2, 2026. The sales were made under a 10b5-1 plan executed July 29, 2026, and were executed in multiple trades through a broker-dealer.

What were Ross Moat's KNSA option exercise prices?

The reported exercise prices were $10.76, $11.10, $11.97, $12.97, $17.76, $18.06, $21.77 and $22.89 per share for option exercises reported on October 30 and November 2, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Moat Ross

(Last)(First)(Middle)
C/O KINIKSA PHARMACEUTICALS INT'L
105 PICCADILLY, SECOND FLOOR

(Street)
LONDONW1J 7NJ

(City)(State)(Zip)

UNITED KINGDOM

(Country)
2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CHIEF OPERATING OFFICER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
10/30/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Ordinary Share10/30/2026M(1)16,111A$10.7632,418D
Class A Ordinary Share10/30/2026M(1)21,059A$11.153,477D
Class A Ordinary Share10/30/2026M(1)3,760A$11.9757,237D
Class A Ordinary Share10/30/2026M(1)1,658A$12.9758,895D
Class A Ordinary Share10/30/2026M(1)16,112A$17.7675,007D
Class A Ordinary Share10/30/2026M(1)10,895A$18.0685,902D
Class A Ordinary Share10/30/2026S(1)37,775D$92(2)48,127D
Class A Ordinary Share10/30/2026S(1)15,114D$92.81(3)33,013D
Class A Ordinary Share10/30/2026S(1)8,430D$93.97(4)24,583D
Class A Ordinary Share10/30/2026S(1)6,282D$94.92(5)18,301D
Class A Ordinary Share10/30/2026S(1)3,672D$96.03(6)14,629D
Class A Ordinary Share10/30/2026S(1)1,760D$97.1(7)12,869D
Class A Ordinary Share10/30/2026S(1)2,575D$97.76(8)10,294D
Class A Ordinary Share11/02/2026M(1)9,412A$18.0619,706D
Class A Ordinary Share11/02/2026M(1)12,302A$21.7732,008D
Class A Ordinary Share11/02/2026M(1)6,263A$22.8938,271D
Class A Ordinary Share11/02/2026S(1)6,681D$91.23(9)31,590D
Class A Ordinary Share11/02/2026S(1)8,932D$92.05(10)22,658D
Class A Ordinary Share11/02/2026S(1)11,642D$93.15(11)11,016D
Class A Ordinary Share11/02/2026S(1)722D$94.05(12)10,294D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Share Option$10.7610/30/2026M(1)16,111 (13)03/31/2033Class A Ordinary Share16,111$07,250D
Share Option$11.110/30/2026M(1)21,059 (14)04/06/2032Class A Ordinary Share21,059$00D
Share Option$11.9710/30/2026M(1)3,760 (14)08/31/2032Class A Ordinary Share3,760$023,492D
Share Option$12.9710/30/2026M(1)1,658 (14)09/01/2031Class A Ordinary Share1,658$00D
Share Option$17.7610/30/2026M(1)16,112 (15)08/31/2033Class A Ordinary Share16,112$011,277D
Share Option$18.0610/30/2026M(1)10,895 (16)03/31/2034Class A Ordinary Share10,895$025,205D
Share Option$18.0611/02/2026M(1)9,412 (16)03/31/2034Class A Ordinary Share9,412$015,793D
Share Option$21.7711/02/2026M(1)12,302 (17)03/31/2035Class A Ordinary Share12,302$027,062D
Share Option$22.8911/02/2026M(1)6,263 (14)03/15/2031Class A Ordinary Share6,263$01,691D
Explanation of Responses:
1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 29, 2026.
2. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $91.36 to $92.35. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
3. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $92.36 to $93.31. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
4. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $93.37 to $94.36. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
5. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $94.375 to $95.215. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
6. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $95.485 to $96.405. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
7. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $96.54 to $97.48. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
8. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $97.60 to $98.30. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
9. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $90.64 to $91.63. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
10. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $91.64 to $92.525. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
11. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $92.732 to $93.725. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
12. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $93.94 to $94.135. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
13. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2023.
14. The option is fully vested and exercisable.
15. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.
16. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2024.
17. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2025.
/s/ Douglas Barry, Attorney-in-Fact11/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading